SRPT:NGS-Sarepta Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 124.25

Change

+7.13 (+6.09)%

Market Cap

USD 1.99B

Volume

1.50M

Analyst Target

USD 193.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
ARGX argenx NV ADR

N/A

USD 23.13B
BNTX BioNTech SE

N/A

USD 22.34B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 19.27B
GMAB Genmab AS

N/A

USD 18.26B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B

ETFs Containing SRPT

PINK Simplify Exchange Traded .. 8.61 % 0.00 %

N/A

USD 0.12B
MSGR 6.12 % 0.00 %

N/A

N/A
XDNA:CA iShares Genomics Immunolo.. 5.39 % 0.00 %

N/A

CAD 4.63M
IBRN iShares Trust - iShares N.. 4.34 % 0.00 %

N/A

USD 3.84M
CURE:XETRA VanEck Genomics and Healt.. 4.07 % 0.00 %

N/A

USD 6.89M
GNOG:LSE Global X Genomics & Biote.. 3.92 % 0.00 %

N/A

USD 8.88M
GN0M:XETRA Global X Genomics & Biote.. 3.83 % 0.00 %

N/A

USD 7.05M
BIOT:SW L&G Pharma Breakthrough U.. 3.61 % 0.00 %

N/A

N/A
CDNA:CA CI Bio-Revolution ETF 2.81 % 0.00 %

N/A

CAD 4.55M
BIGT:LSE L&G Pharma Breakthrough U.. 2.45 % 0.00 %

N/A

USD 0.02B
WELL:LSE Hanetf Icav - Han-Gins He.. 1.54 % 0.00 %

N/A

USD 0.02B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.45 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.41 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.41 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 1.06 % 0.00 %

N/A

USD 0.04B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD 0.02B
JKJ iShares Morningstar Small.. 0.00 % 0.25 %

N/A

USD 0.21B
JKK iShares Morningstar Small.. 0.00 % 0.30 %

N/A

USD 0.52B
LABS 0.00 % 0.45 %

N/A

N/A
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

N/A

USD 0.04B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

N/A

USD 0.09B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B
DWEQ 0.00 % 0.00 %

N/A

N/A
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

N/A

USD 0.52B
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.85% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.85% 78% C+ 87% B+
Trailing 12 Months  
Capital Gain 1.61% 66% D+ 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.61% 66% D+ 49% F
Trailing 5 Years  
Capital Gain 2.52% 73% C 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.52% 73% C 50% F
Average Annual (5 Year Horizon)  
Capital Gain 9.93% 67% D+ 70% C-
Dividend Return 9.93% 67% D+ 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.76% 59% D- 35% F
Risk Adjusted Return 20.80% 76% C+ 58% F
Market Capitalization 1.99B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 13.65 11% 8%
Price / Cash Flow Ratio -23.89 95% 89%
Price/Free Cash Flow Ratio -25.23 96% 91%
Management Effectiveness  
Return on Equity -86.15% 45% 22%
Return on Invested Capital -14.09% 83% 37%
Return on Assets -5.24% 94% 40%
Debt to Equity Ratio 131.79% 14% 18%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.